Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02129062
Title Ibrutinib in Treating Patients With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
City of Hope Comprehensive Cancer Center Duarte California 91010 United States Details
USC / Norris Comprehensive Cancer Center Los Angeles California 90033 United States Details
UC Davis Comprehensive Cancer Center LAPS Sacramento California 95817 United States Details
Moffitt Cancer Center Tampa Florida 33612 United States Details
University of Chicago Comprehensive Cancer Center Chicago Illinois 60637 United States Details
Rutgers Cancer Institute of New Jersey New Brunswick New Jersey 08903 United States Details
Penn State Milton S Hershey Medical Center Hershey Pennsylvania 17033-0850 United States Details
M D Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field